Browsing Category
Featured Articles
Gilead Partners with PEPFAR to Provide Twice-Yearly HIV Prevention to 2 Million People in Low-Income…
Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's…
Read More...
Read More...
Amgen to Invest Over $600 Million in New Science and Innovation Center at U.S. Headquarters
Amgen has announced plans to invest more than $600 million in a cutting-edge center for science and innovation at its global headquarters in Thousand Oaks, California. The new facility…
Read More...
Read More...
Boehringer’s HERNEXEOS Approved in China as First Oral Targeted Therapy for HER2-Mutant Advanced…
Boehringer Ingelheim announced that its drug HERNEXEOS (zongertinib tablets) has received approval from China’s National Medical Products Administration (NMPA) as a monotherapy…
Read More...
Read More...
Novartis’ Leqvio Achieves Early LDL-C Goals with Less Muscle Pain
Novartis has announced encouraging results from its Phase IV V-DIFFERENCE study, which evaluated Leqvio (inclisiran) in patients with high cholesterol who had not met…
Read More...
Read More...
RINVOQ Receives Health Canada Approval for Giant Cell Arteritis in Adults
AbbVie announced that Health Canada has granted a Notice of Compliance (NOC) for RINVOQ (upadacitinib) for the treatment of adults with giant cell arteritis (GCA). The approval includes…
Read More...
Read More...
DATROWAY Approved in China for Previously Treated HR+/HER2- Metastatic Breast Cancer
China’s National Medical Products Administration (NMPA) has approved DATROWAY (datopotamab deruxtecan) for the treatment of adults with unresectable or metastatic hormone receptor (HR)…
Read More...
Read More...
Genentech and Roche Break Ground on New Manufacturing Facility in North Carolina
Genentech, a member of the Roche Group, officially broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina, marking a major milestone as the biotech giant…
Read More...
Read More...
AbbVie to Acquire Gilgamesh’s Bretisilocin, Boosting Psychiatry Pipeline for Depression
AbbVie and Gilgamesh Pharmaceuticals have entered into a definitive agreement under which AbbVie will acquire Gilgamesh’s lead investigational candidate, bretisilocin, a next-generation…
Read More...
Read More...
Lilly’s Oral GLP-1, Orforglipron, Succeeds in Third Phase 3 Trial, Paving Way for Global Obesity…
Eli Lilly and Company announced that its investigational oral GLP-1 receptor agonist, orforglipron, delivered significant weight loss and blood sugar control in a Phase 3 clinical trial…
Read More...
Read More...
Kite to Acquire Interius BioTherapeutics to Expand In Vivo Cell Therapy Capabilities
Kite, a Gilead Company, announced it will acquire Interius BioTherapeutics, a privately held biotech firm pioneering in vivo CAR therapies, in a $350 million deal aimed at advancing…
Read More...
Read More...
Johnson & Johnson Invests $2B in New State-of-the-Art Manufacturing Facility in North Carolina
Johnson & Johnson has announced a major expansion of its U.S. manufacturing capabilities with a $2 billion, 10-year investment in a new 160,000+ square foot facility at FUJIFILM’s…
Read More...
Read More...
Jazz Pharmaceuticals Signs Exclusive Licensing Deal with Saniona for SAN2355 Development
Jazz Pharmaceuticals plc and Saniona have entered into a global licensing agreement granting Jazz exclusive worldwide rights to develop and commercialize SAN2355, a subtype-selective…
Read More...
Read More...
Boehringer Ingelheim, AnGes Ink Manufacturing Deal for HGF Gene Therapy
Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes Inc. to produce the drug substance for AnGes' investigational Hepatocyte Growth Factor…
Read More...
Read More...
European Commission Approves OGSIVEO for Adult Desmoid Tumors
SpringWorks Therapeutics, part of Merck KGaA, Darmstadt, Germany, announced that the European Commission (EC) has granted marketing authorization for OGSIVEO (nirogacestat), an oral…
Read More...
Read More...
FDA Grants Breakthrough Status to Izalontamab Brengitecan for EGFR-Mutant Lung Cancer
SystImmune Inc. and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan…
Read More...
Read More...
FDA Grants Accelerated Approval to Boehringer’s HERNEXEOS for HER2-Mutant Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to HERNEXEOS (zongertinib tablets), Boehringer Ingelheim’s new oral targeted therapy for adults with…
Read More...
Read More...
FDA Grants Priority Review to Gepotidacin for Oral Treatment of Gonorrhea
GSK announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for gepotidacin, an oral antibiotic, for the treatment of…
Read More...
Read More...
FDA Expands Approval of AJOVY as First Anti-CGRP Preventive for Pediatric Episodic Migraine
In a significant development for pediatric migraine care, Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for AJOVY…
Read More...
Read More...
FDA Accepts Bristol Myers Squibb’s Priority Review for Breyanzi in Relapsed/Refractory Marginal Zone…
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) for Breyanzi (lisocabtagene…
Read More...
Read More...
AstraZeneca and Revna Biosciences Expand Lung Cancer Treatment Access in Ghana
Since announcing their partnership in April 2025, AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care across Ghana, from early diagnosis to…
Read More...
Read More...
